The clinical use of the transthyretin stabilizer (tafamidis), the first ATTR-CM treatment approved by the United States Food and Drug Administration (FDA), has proven benefits with regard to mortality, hospitalization, and quality of life in both ATTRwt-CM and ATTRv-CM.19,41 Two TTR silencing drugs that significantly reduce the production of TTR by the liver—patisiran and inotersen—are FDA approved for the treatment of neuropathy in ATTRv, with clinical trials of silencer therapy in ATTR-CM either in progress or recently completed.42,43. Here, TTR is linked to neuropathy.